[Experimental and clinical evaluation of latamoxef in newborn and premature infants].
Fundamental and clinical studies in infants including neonates on latamoxef (LMOX) were carried out, and following results were obtained. In fundamental studies, half-lives of LMOX were 5.79, 4.38 hours, at dose 10 mg/kg by intravenous injection and intravenous drip infusion in neonates, respectively. And urinary excretions were 6.8, 15.6% for 6 hours, respectively. In 28--50 day-old neonates, half-lives were 2.26--4.3 hours at dose 20 mg/kg, and urinary excretions were ranged from 14.3 to 37.0%. Clinical results were following. In 8 cases of bronchopneumonia and 2 cases of pertussis, the clinical efficacy rate was 100% at daily dose 38--100 mg/kg twice or third a day by intravenous injection or intravenous drip infusion for 6--9 days duration. All causative organisms (K. pneumoniae 1, S. aureus 1) were eliminated after LMOX 43 or 38 mg/kg/day dose administration. Side effect and laboratory abnormal value were not noticed in all cases. We finally have a conclusion that LMOX should be administered 40--70 mg/kg/day, and given twice or third a day by intravenous injection or intravenous drip infusion.
D001424:Bacterial Infections / Q000188:drug therapy*; D001996:Bronchopneumonia / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008297:Male; D009070:Moxalactam / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D014917:Whooping Cough / Q000188:drug therapy
D009070:Moxalactam